Skip to main content
Top
Published in: Breast Cancer Research 3/2007

Open Access 01-06-2007 | Research article

Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women

Authors: Ahmedin Jemal, Elizabeth Ward, Michael J Thun

Published in: Breast Cancer Research | Issue 3/2007

Login to get access

Abstract

Introduction

A recent abstract presented in a breast cancer symposium attributed the sharp decrease in female breast cancer incidence rates from 2002 to 2003 in the Surveillance, Epidemiology, and End Results (SEER) cancer registries of the United States to the reduced use of hormone replacement therapy since July 2002. However, this hypothesis does not explain the decrease that began in 1999 in the age-standardized incidence rate of invasive breast cancer in the nine oldest SEER cancer registry areas, although the trend through 2003 was not statistically significant. In this paper, we examine temporal trends in invasive and in situ female breast cancer by age, stage, tumor size, and estrogen receptor/progestin receptor (ER/PR) status in the nine oldest SEER cancer registry areas and consider the implication of these trends in relation to risk factors and screening.

Methods

We performed a joinpoint regression analysis to fit a series of joined straight lines to the trends in age-adjusted rates and described the resultant trends (slope) by annual percentage change (two-sided, P < 0.05).

Results

A plot of the age-specific rates of invasive breast cancer shows a decrease in all 5-year age groups from 45 years and above between 1999 and 2003 and sharp decreases largely confined to ER+ tumors in age groups from 50 to 69 years between 2002 and 2003. In joinpoint analyses by tumor size and stage, incidence rates decreased for small tumors (less than or equal to 2 cm) by 4.1% (95% confidence interval [CI], 0.2% to 7.8%) per year from 2000 through 2003 and for localized disease by 3.1% (95% CI, 1.2% to 5.0%) per year from 1999 through 2003. No decrease in incidence was observed for larger tumors or advanced-stage disease during the corresponding periods. Rates for in situ disease were stable from 2000 through 2003 after increasing rapidly since 1981.

Conclusion

Two distinct patterns are observed in breast cancer trends. The downturn in incidence rates in all age groups above 45 years suggests a period effect that is consistent with saturation in screening mammography. The sharp decrease in incidence from 2002 to 2003 that occurred in women 50 to 69 years old who predominantly, but not exclusively, had ER+ tumors may reflect the early benefit of the reduced use of hormone replacement therapy.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Howe HL, Wu X, Ries LA, Cokkinides V, Ahmed F, Jemal A, Miller B, Williams M, Ward E, Wingo PA, et al: Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer. 2006, 107: 1711-1742. 10.1002/cncr.22193.CrossRefPubMed Howe HL, Wu X, Ries LA, Cokkinides V, Ahmed F, Jemal A, Miller B, Williams M, Ward E, Wingo PA, et al: Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer. 2006, 107: 1711-1742. 10.1002/cncr.22193.CrossRefPubMed
3.
go back to reference Miller BA, Feuer EJ, Hankey BF: The increasing incidence of breast cancer since 1982: relevance of early detection. Cancer Causes Control. 1991, 2: 67-74. 10.1007/BF00053123.CrossRefPubMed Miller BA, Feuer EJ, Hankey BF: The increasing incidence of breast cancer since 1982: relevance of early detection. Cancer Causes Control. 1991, 2: 67-74. 10.1007/BF00053123.CrossRefPubMed
4.
go back to reference White E, Lee CY, Kristal AR: Evaluation of the increase in breast cancer incidence in relation to mammography use. J Natl Cancer Inst. 1990, 82: 1546-1552. 10.1093/jnci/82.19.1546.CrossRefPubMed White E, Lee CY, Kristal AR: Evaluation of the increase in breast cancer incidence in relation to mammography use. J Natl Cancer Inst. 1990, 82: 1546-1552. 10.1093/jnci/82.19.1546.CrossRefPubMed
5.
go back to reference Garfinkel L, Boring CC, Heath CW: Changing trends. An overview of breast cancer incidence and mortality. Cancer. 1994, 74 (1 Suppl): 222-227.CrossRefPubMed Garfinkel L, Boring CC, Heath CW: Changing trends. An overview of breast cancer incidence and mortality. Cancer. 1994, 74 (1 Suppl): 222-227.CrossRefPubMed
6.
go back to reference Anderson WF, Jatoi I, Devesa SS: Assessing the impact of screening mammography: breast cancer incidence and mortality rates in Connecticut (1943–2002). Breast Cancer Res Treat. 2006, 99: 333-340. 10.1007/s10549-006-9214-z.CrossRefPubMed Anderson WF, Jatoi I, Devesa SS: Assessing the impact of screening mammography: breast cancer incidence and mortality rates in Connecticut (1943–2002). Breast Cancer Res Treat. 2006, 99: 333-340. 10.1007/s10549-006-9214-z.CrossRefPubMed
7.
go back to reference Blot WJ, Devesa SS, Fraumeni JF: Declining breast cancer mortality among young American women. J Natl Cancer Inst. 1987, 78: 451-454.PubMed Blot WJ, Devesa SS, Fraumeni JF: Declining breast cancer mortality among young American women. J Natl Cancer Inst. 1987, 78: 451-454.PubMed
8.
go back to reference Tarone RE, Chu KC: Implications of birth cohort patterns in interpreting trends in breast cancer rates. J Natl Cancer Inst. 1992, 84: 1402-1410. 10.1093/jnci/84.18.1402.CrossRefPubMed Tarone RE, Chu KC: Implications of birth cohort patterns in interpreting trends in breast cancer rates. J Natl Cancer Inst. 1992, 84: 1402-1410. 10.1093/jnci/84.18.1402.CrossRefPubMed
9.
go back to reference Surveillance, Epidemiology, and End Results (SEER) Program. Delay-Adjusted Incidence database: "SEER Incidence Delay-Adjusted Rates, 9 Registries, 1975–2003". National Cancer Institute, DCCPS, Surveillance Research Program, Statistical Research and Applications Branch, released April based on the November 2005 SEER data submission. [http://srab.cancer.gov/delay/canques.html] Surveillance, Epidemiology, and End Results (SEER) Program. Delay-Adjusted Incidence database: "SEER Incidence Delay-Adjusted Rates, 9 Registries, 1975–2003". National Cancer Institute, DCCPS, Surveillance Research Program, Statistical Research and Applications Branch, released April based on the November 2005 SEER data submission. [http://​srab.​cancer.​gov/​delay/​canques.​html]
10.
go back to reference Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF: Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002, 94: 1537-1545.CrossRefPubMed Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF: Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002, 94: 1537-1545.CrossRefPubMed
11.
go back to reference Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence – SEER 9 Regs Public-Use, Nov 2005 Sub (1973–2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April based on the November 2005 submission. [http://www.seer.cancer.gov/data] Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence – SEER 9 Regs Public-Use, Nov 2005 Sub (1973–2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April based on the November 2005 submission. [http://​www.​seer.​cancer.​gov/​data]
12.
go back to reference Kim HJ, Fay MP, Feuer EJ, Midthune DN: Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000, 19: 335-351. 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z.CrossRefPubMed Kim HJ, Fay MP, Feuer EJ, Midthune DN: Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000, 19: 335-351. 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z.CrossRefPubMed
13.
go back to reference Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S, (Eds): International Classification of Diseases for Oncology. 2000, Geneva: World Health Organization, 3 Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S, (Eds): International Classification of Diseases for Oncology. 2000, Geneva: World Health Organization, 3
14.
go back to reference Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C: Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996, 275: 913-918. 10.1001/jama.275.12.913.CrossRefPubMed Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C: Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996, 275: 913-918. 10.1001/jama.275.12.913.CrossRefPubMed
15.
go back to reference National Center for Health Statistics: Health, United States, 2005, With Chartbook on Trends in the Health of Americans. 2005, Hyattsville, MD: National Center for Health Statistics National Center for Health Statistics: Health, United States, 2005, With Chartbook on Trends in the Health of Americans. 2005, Hyattsville, MD: National Center for Health Statistics
16.
go back to reference Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRefPubMed Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRefPubMed
17.
go back to reference Hersh AL, Stefanick ML, Stafford RS: National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004, 291: 47-53. 10.1001/jama.291.1.47.CrossRefPubMed Hersh AL, Stefanick ML, Stafford RS: National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004, 291: 47-53. 10.1001/jama.291.1.47.CrossRefPubMed
18.
go back to reference Majumdar SR, Almasi EA, Stafford RS: Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA. 2004, 292: 1983-1988. 10.1001/jama.292.16.1983.CrossRefPubMed Majumdar SR, Almasi EA, Stafford RS: Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA. 2004, 292: 1983-1988. 10.1001/jama.292.16.1983.CrossRefPubMed
Metadata
Title
Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women
Authors
Ahmedin Jemal
Elizabeth Ward
Michael J Thun
Publication date
01-06-2007
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 3/2007
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1672

Other articles of this Issue 3/2007

Breast Cancer Research 3/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine